Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature
- 1 May 2014
- journal article
- clinical trial
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 32 (4), 480-487
- https://doi.org/10.1016/j.urolonc.2013.10.004
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Contrasting the vascular response to sunitinib as measured by DCE-CT, DCE-MRI, and DCE-US.Journal of Clinical Oncology, 2013
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2012
- Improved Flow Measurement Using Microbubble Contrast Agents and Disruption-Replenishment: Clinical Application to Tumour MonitoringJapanese Journal of Clinical Oncology, 2011
- Dynamic Microbubble Contrast-enhanced US to Measure Tumor Response to Targeted Therapy: A Proposed Clinical Protocol with Results from Renal Cell Carcinoma Patients Receiving Antiangiogenic TherapyRadiology, 2011
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysisCancer Chemotherapy and Pharmacology, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology PatientsClinical Cancer Research, 2009
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Rapid vascular regrowth in tumors after reversal of VEGF inhibitionJournal of Clinical Investigation, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006